What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “iSCIB1+ is a DNA-based therapeutic cancer vaccine designed to enhance T-cell immune responses against melanoma-associated antigens. The vaccine encodes epitopes derived from glycoprotein 100 (gp100) and tyrosinase-related protein 2 (TRP-2) that are delivered using Scancell's ImmunoBody® platform. In this study, iSCIB1+ is administered by intramuscular injection with electroporation in combination…”In the company’s words, NCT07815574 on ClinicalTrials.gov
- Tested for
- Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer, Malignant Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV
- Main trialPhase 3
- “This Phase 3 clinical trial is evaluating whether adding iSCIB1+, an investigational DNA-based cancer vaccine, to standard immunotherapy with nivolumab and ipilimumab can improve outcomes for people with advanced unresectable melanoma. Participants will be randomly assigned to receive either iSCIB1+ or a placebo, in addition to standard treatment with nivolumab and ipilimumab. Neither participants nor study doctors will know which treatment has been assigned. The study will compare how long participants live without their cancer worsening, overall survival, tumor response, safety, and…”In the company’s words, NCT07815574 on ClinicalTrials.gov
- Other names
- ImmunoBody
Other drugs for Melanoma (Skin Cancer)
- PembrolizumabMerck & Co. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
- BCD-217Biocad · Phase 3
- NaporafenibErasca · Novartis Pharmaceuticals · Phase 3
Coming up2
- 31 Jan 2027Phase 2 trial completes · ClinicalTrials.gov
- 1 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 1 Dec 2028 | iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma | |
| Phase 2Active, not recruiting | 31 Jan 2027 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026